When new drugs are approved, the marketing authorization holders often have to commit themselves to perform additional post-authorization studies. These studies have a different set up. Most countries have adjusted the regulations for studies where the drug is commercially available; although there is no "one fits all" concept.
PRA in China
The expertise of a global CRO + local know-how to deliver the highest caliber of clinical development services around the world.
Real World Solutions
PRA Health Sciences’ Real World Solutions team guides clients through the intricacies of real world research throughout the development life cycle.…
PRA Insights Report 2017 ISPOR-EU Survey Results
As our industry landscape for Real World Research has changed exponentially, our Real World Solutions team performed a short questionnaire at ISPOR…